For years, the European chemical industry has been waiting for the same sequence of events: demand recovery, higher operating rates, tighter supply and eventually a return to more sustainable margins. But an uncomfortable question is becoming increasingly difficult to ignore. What if the industry is not simply in a prolonged downcycle? What if part of the European chemical industry has fundamentally lost its previous competitive position?
The challenges facing the sector are well known: energy and feedstock costs, weak industrial demand, persistent global overcapacity, increasing import pressure and rising regulatory and carbon-related costs. Individually, none of these challenges is entirely new. Together, they are changing the economics of the industry.
The more important question for European chemical companies is therefore no longer simply when demand will recover. It is: which assets, value chains and businesses will still be competitive when it does?
Demand recovery will not solve every problem
A recovery in demand would undoubtedly improve operating rates and provide some relief to margins. But higher utilization alone does not automatically restore competitiveness. If a European producer remains structurally disadvantaged against imports or against newer, larger and more integrated assets elsewhere, a cyclical recovery may simply delay a more difficult decision.
This distinction is critical. The traditional industry cycle assumed that periods of weak profitability would eventually lead to capacity rationalization, tighter markets and a subsequent recovery. But the current environment is more complex, because surplus capacity is increasingly global. Capacity that becomes uncompetitive in Europe does not necessarily disappear from the global market; it may continue to operate in China, the Middle East, the United States or other regions with different feedstock economics, energy costs, policy environments or domestic demand dynamics.
LyondellBasell's exit from Brindisi is a small illustration of a large pattern. One site closing is not, by itself, a thesis. But it reflects the same set of pressures now facing much of Europe's asset base: higher production costs than competing regions, growing import pressure from the Middle East and Asia, weak demand growth across several downstream sectors, and an ageing asset base requiring significant reinvestment. Producers are increasingly being forced to judge whether older assets remain competitive over a full cycle, not just through the current one.
European producers are therefore not simply competing against neighbouring plants. They are increasingly competing against the economics of the global chemical system.
From portfolio management to asset selection
One of the most important shifts now taking place is the need to look beyond broad business or portfolio-level assessments. Not all chemical value chains face the same level of structural pressure. A highly differentiated specialty material serving technically demanding applications may remain globally competitive despite Europe's higher operating costs. An integrated producer with strong feedstock access, captive downstream demand or strategic infrastructure may also retain a defensible position. At the other end of the spectrum are products that are highly commoditized, energy intensive, globally traded and increasingly supplied from regions with significant cost or scale advantages.
Lumping these businesses together under the broad heading of "European chemicals" is becoming increasingly unhelpful. The real analysis needs to go deeper: which product is competitive, which asset is competitive, which customer relationship is defensible, which value chain still has a reason to remain in Europe.
Three ways to remain defensible, and one dangerous position
European chemical companies increasingly need to define where their competitive advantage actually comes from. There are broadly three ways a chemical business can remain strategically defensible.
The first is cost and scale: a genuinely competitive position based on feedstock, energy, technology, asset efficiency, scale or logistics. The second is integration: an asset that remains viable because it sits inside a broader industrial ecosystem, with integrated feedstock, intermediates, infrastructure or downstream demand that improves the economics of the overall value chain. The third is differentiation, particularly relevant for specialty chemicals and advanced materials, where application expertise, technical service, product performance, customer qualification and long development cycles create barriers that go beyond simple production cost.
The challenge arises when a business has none of these advantages. A commodity producer without a meaningful cost advantage is exposed. A specialty producer without genuine differentiation is exposed. An asset without sufficient integration may struggle to justify continued investment. The industry can no longer afford to remain strategically ambiguous.
Prismane Consulting's perspective: the selection is already happening
This is not a forecast. Across the chains we track, the 2026 transaction record already reads as an industry sorting its assets against exactly these three tests.
Cost and scale: the polyamide chain shows what happens when the test is failed. Upstream, Europe's production base continues to weaken. BASF is progressing with the phased consolidation of its Ludwigshafen caprolactam capacity, a deliberate, long-planned reduction rather than an abrupt shutdown, with production cut meaningfully and some precursor units closed while output continues at reduced levels. DOMO's German resin subsidiaries, including the historic Leuna caprolactam and PA6 operations, filed for insolvency in late 2025 after prolonged pressure from weak demand, high production costs and competitively priced imports. The rescue vehicle established to save the site, Leuna Polyamid, has since entered insolvency proceedings itself, less than three months after being formed.
The contrast between those two outcomes is the more instructive part. One is a managed consolidation, executed to a plan over several years. The other was a genuine rescue attempt undone within weeks by a geopolitical shock that repriced its entire feedstock and energy cost base before any financial buffer could be built. Both end in the same place: Germany's domestic caprolactam production base is under severe strain, and Europe's downstream polyamide industry may have to lean on imports to fill a gap that was, until recently, treated as secure domestic supply.
Integration: the RadiciGroup–DOMO combination is a bet on it. DOMO Engineered Materials has been combined with RadiciGroup to create a global engineered materials platform spanning Europe, the Americas and Asia, operating under the RadiciGroup, DOMO and TECHNYL® brands. The strategic nuance sits in where integration now resides. The platform's compounding network stretches from Ohio to Suzhou, but its polymer backbone is entirely European: RadiciGroup's polymerization and intermediates assets in Italy and Germany. DOMO's legacy polymerization operations, including the PA66 business at Belle Étoile under judicial administration, remain outside the transaction perimeter.
That is more than a consolidation of compounders. It is a bet that compounding competitiveness increasingly depends on access to integrated, cost-efficient polymer production, precisely the capability Europe is losing fastest. Whether that bet pays depends on whether integrated European producers can withstand the structural cost advantage of imports over the coming decade.
Differentiation: the conglomerate is being unbundled to get at it. The separation of BASF's Coatings business into Surventis moved from deal to execution this year, with the business taking over as an independent company on 1 July 2026 following the Carlyle and Qatar Investment Authority transaction, valuing it at €7.7 billion enterprise value (€8.7 billion for the full Coatings division including the earlier decorative paints sale), with BASF retaining 40% on roughly €3.7 billion of 2025 sales. Our reading is that this is a deliberate unbundling of the integrated chemical conglomerate. Scale in basic chemicals is increasingly a cost to manage, while application-driven businesses get positioned to compete on speed. With tariffs and CBAM reshaping trade, a focused coatings platform with its own capital allocation is not a demotion; it is a competitive weapon.
Capital is still flowing toward European differentiation where the application pull is real. WACKER has brought a new specialty silicones plant online in Karlovy Vary, targeting EVs, medical technology and energy, part of a wider wave in which Dow has committed roughly $100 million through 2027 across the US, China and Japan, Shin-Etsu has scaled Pinghu, and Elkem opened a high-purity medical-grade plant in South Carolina. When four of the world's largest silicones producers converge on the same three end markets inside the same twelve to eighteen months, the demand signal has usually been validated industry-wide. Notably, this capital is being deployed local-for-local (near the battery lines, the fabs and the medical device plants), not simply where production is cheapest. Differentiation, in other words, is not only about the molecule; it is about proximity to the qualification.
Stuck in the middle: Synthomer's exit from Sokolov is the clearest signal in the set. The Acrylate Monomers plant in Sokolov, Czech Republic produces acrylic acid, a key raw material for coatings, adhesives and superabsorbent polymers; on Prismane Consulting's capacity database the site holds 55 ktpa of acrylic acid and around 75 ktpa of acrylates. It lost €10 million in EBITDA in 2025, though trading had recovered to breakeven by early 2026, and it required around €5 million a year in capex in one of the most cyclical corners of the industry. Synthomer handed it to Mutares with zero upfront cash and a potential €12 million earn-out over three years.
The timing is the point. They exited as the business was recovering. That is what it looks like when a producer concludes the problem is structural rather than cyclical, and it is the same conclusion visible in Mutares' acquisition of SABIC's Engineering Thermoplastics business, which we examined in The Engineering Plastics & Composites Industry Isn't Recovering. It's Changing Hands. In a market where Asian capacity is relentless, owning a base chemicals plant without a cost, integration or differentiation advantage is no longer a strength.
The counter-case: rationalization can also create winners
None of this justifies a uniformly pessimistic reading, and the strongest challenge to the argument above comes from within the same evidence base.
Western European PVC has been in genuine distress. Vynova's Beek facility in the Netherlands closed last year, removing 225 kt of capacity; INEOS Inovyn mothballed two UK lines in 2024; the Martorell plant in Spain halved its output. In total the market has lost roughly 700 kt since 2024, against a Western European base of only around 6,000 kt. Into that gap stepped Westlake Vinnolit, acquiring Vynova Group's insolvent PVC and VCM facility at Wilhelmshaven from the insolvency estate: 380 kt/year of capacity, around 350 jobs and a deep-water dock on Germany's North Sea coast, taking it from 768 kt to 1,148 kt of Western European capacity and making it the region's third-largest producer.
Yet the restructuring story has taken a more nuanced turn. As part of the broader portfolio overhaul, the plan for the Netherlands' Beek plant has shifted: rather than remaining permanently shuttered, it is now slated to restart by October 2026. Meanwhile, the Belgian site at Tessenderlo and the French facility at Mazingarbe are being prepared for sale to separate investors rather than restarted. In other words, rationalization in this chain is not a simple retreat, but a selective reshaping of the asset footprint, where some assets are revived (Beek) and others are divested (Tessenderlo, Mazingarbe).
That is the counter-argument to a purely structural pessimism: if rationalization is deep enough, disciplined enough and strategically selective, the surviving assets in a chain can become genuinely attractive, and a counter-cyclical buyer with the right cost position can pick up capacity that competitors have just abandoned. The distinction matters. Rationalization is not the same as decline. In some chains it is the mechanism by which a defensible European position is rebuilt around fewer, better-placed assets.
But note what makes Westlake's move work: an existing competitive position, an infrastructure advantage in the deep-water dock, and a chain where the capacity being removed is genuinely leaving the regional market (or, in Beek's case, being revived under a different cost structure). Those conditions do not hold everywhere. Where surplus capacity simply relocates to a lower-cost region rather than disappearing, European closures tighten nothing.
Green chemistry will create opportunities, but not evenly
Europe has strong ambitions around circularity, recycling, low-carbon production and sustainable materials, and these trends will undoubtedly create new markets. But sustainability does not eliminate the underlying economics of chemical production. A low-carbon molecule still needs a customer willing to pay for it. A recycled or bio-based material still needs to compete on performance, availability and price. A producer investing heavily in decarbonization still needs to generate an adequate return.
What the recent investment record suggests is that the adoption barrier matters at least as much as the carbon saving. Catalyxx's approval for its first commercial-scale plant producing butanol, hexanol and octanol from bioethanol rather than fossil feedstocks deserves more attention than it has received, not because the products are bio-based, but because they are chemically identical to conventional petrochemicals. Same specifications, same downstream infrastructure, same customer base. Nothing downstream has to change.
That is the distinction we would draw. Many bio-based chemicals struggle because they require customers to reformulate products or modify existing processes. Drop-in chemistries do not. The same pattern is emerging across renewable methanol, sustainable aviation fuel intermediates and bio-based olefins, where investment increasingly favours drop-in solutions that leverage existing infrastructure over entirely new molecular platforms. The next phase of chemical decarbonization may be less about inventing new molecules than about reinventing how the existing ones are made.
The danger remains in assuming the entire industry can transition to higher-cost, lower-carbon production and recover the difference through a "green premium." Certain sectors may support one, particularly where regulation, brand positioning or customer commitments create a clear willingness to pay. Others will not. The market will be far more selective than that.
The next chemical cycle may look very different
The chemical industry will recover. Demand cycles will continue. Operating rates will improve in some value chains. But it may be a mistake to assume the next recovery will restore the industry that existed before the downturn. Some European assets will emerge stronger because they are technologically differentiated, strategically integrated or genuinely competitive. Others will continue to face pressure even in a stronger demand environment.
That is why the discussion needs to move beyond forecasting market growth. For chemical companies, investors and policymakers, the more important questions increasingly involve asset competitiveness, trade exposure, cost position, integration and the probability of capacity rationalization. The future of the industry will not be determined only by who can predict demand growth most accurately. It will also be determined by who can identify, early enough, which parts of the value chain have a sustainable right to exist.
The European chemical industry does not simply have a demand problem. In many value chains, it has an asset competitiveness problem. And that distinction will define the industry's next decade.
Interested in understanding how these dynamics affect your asset footprint, portfolio strategy or investment decisions in Europe or elsewhere? Get in touch with Prismane Consulting.
Company transactions and results cited above are drawn from public announcements. Capacity, trade and market-share figures are based on Prismane Consulting's market intelligence and databases.